Tadayoshi Miyagi

Tadayoshi Miyagi

Auto-generated profile, based on publicly available information

Tadayoshi Miyagi

Division of Cardiology, Okinawa Prefectural Chubu Hospital, Uruma, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
SHSatoshi Honda
Satoshi Honda
YAYasuhide Asaumi
Yasuhide Asaumi
TYTakafumi Yamane
Takafumi Yamane
TNToshiyuki Nagai
Toshiyuki Nagai
TMTadayoshi Miyagi
Tadayoshi Miyagi
SYSatoshi Yasuda
Satoshi Yasuda
Background: There is little known about whether the clinical and pathological characteristics and incidence of cardiac rupture ( CR ) in patients with acute myocardial infarction ( AMI ) have changed over the years. Methods and Results: The incidence and clinical characteristics of CR were investigated in patients with AMI , who were divided into 3 cohorts: 1977–1989, 1990–2000, and 2001–2011. Of a total of 5699 patients, 144 were diagnosed with CR and 45 survived. Over the years, the incidence of CR decreased (1977–1989, 3.3%; 1990–2000, 2.8%; 2001–2011, 1.7%; P =0.002) in association with the widespread adoption of reperfusion therapy. The mortality rate of CR decreased (1977–1989, 90%; 1990–2000, 56%; 2001–2011, 50%; P =0.002) in association with an increase in the rate of emergent surgery. In multivariable analysis, first myocardial infarction, anterior infarct, female sex, hypertension, and age >70 years were significant risk factors for CR , whereas impact of hypertension on CR was weaker from 2001 to 2011. Primary percutaneous coronary intervention ( PPCI ) was a significant protective factor against CR . In 64 autopsy cases with CR , myocardial hemorrhage occurred more frequently in those who underwent PPCI or fibrinolysis than those who did not receive reperfusion therapy (no reperfusion therapy, 18.0%; fibrinolysis, 71.4%; PPCI , 83.3%; P =0.001). Conclusions: With the development of medical treatment, the incidence and mortality rate of CR have decreased. However, first myocardial infarction, anterior infarct, female sex, and old age remain important risk factors for CR . Adjunctive cardioprotection against reperfusion‐induced myocardial hemorrhage is emerging in the current PPCI era.

1 June 2015 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
YAYasuhide Asaumi
Yasuhide Asaumi
TNTeruo Noguchi
Teruo Noguchi
YMYoshiaki Morita
Yoshiaki Morita
RFReiko Fujiwara
Reiko Fujiwara
TKTomoaki Kanaya
Tomoaki Kanaya
SYSatoshi Yasuda
Satoshi Yasuda

1 September 2016 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
TMTadayoshi Miyagi
Tadayoshi Miyagi
YAYasuhide Asaumi
Yasuhide Asaumi
KNKunihiro Nishimura
Kunihiro Nishimura
TNTakahiro Nakashima
Takahiro Nakashima
HSHiroki Sakamoto
Hiroki Sakamoto
SYSatoshi Yasuda
Satoshi Yasuda
Background—: The efficacy and prognosis of percutaneous coronary intervention (PCI) as secondary revascularization in patients with previous coronary artery bypass graft surgery remain uncertain. Methods and Results—: We retrospectively evaluated 434 consecutive patients with previous coronary artery bypass graft surgery hospitalized for PCI between 2004 and 2011 (men 84%, age 71 (interquartile range, 66–76) years) and calculated the coronary artery bypass graft Synergy Between Percutaneous Coronary Intervention With Taxus score (CSS) before (baseline CSS) and after PCI (post-PCI CSS). Patients were divided into 2 groups based on median post-PCI CSS: low-score (≤23; n=217) and high-score groups (>23; n=217). Major adverse cardiovascular events (MACE) were defined as the composite of cardiovascular death, myocardial infarction, and unplanned repeat revascularization for myocardial ischemia. The median baseline and post-PCI CSS were 30 (interquartile range, 21–40) and 23 (interquartile range, 14.5–33.5), respectively. During a median follow-up of 69 months, the prevalence of MACE and cardiac death differed significantly between the 2 post-PCI CSS groups (MACE: low, 13.8%; high, 28.6%; P <0.001; cardiac death: low, 6.2%; high, 16.7%; P =0.002). In multivariable analysis, the high post-PCI CSS divided by the median was associated with substantially greater cumulative MACE (hazard ratio, 2.09; 95% confidence interval, 1.31–3.34; P =0.002) and cardiac death (hazard ratio, 2.02; 95% confidence interval, 1.03–3.98; P =0.042) compared with the low post-PCI CSS. Net reclassification improvement analysis revealed that post-PCI CSS resulted in significantly improved prediction of MACE and cardiac death compared with baseline CSS. Conclusions—: In this external validation study, the CSS was a potential prognostic factor after subsequent PCI, even for previous coronary artery bypass graft surgery patients.

12 April 2018 in The American Journal of Cardiology
Verified
Journal Article
Open access
PDF file
YNYuichi Nakamura
Yuichi Nakamura
YAYasuhide Asaumi
Yasuhide Asaumi
TMTadayoshi Miyagi
Tadayoshi Miyagi
MNMichikazu Nakai
Michikazu Nakai
KNKunihiro Nishimura
Kunihiro Nishimura
SYSatoshi Yasuda
Satoshi Yasuda
Patients with coronary artery disease (CAD) need systemic management in addition to coronary revascularization to improve clinical outcomes. Many studies and guidelines have shown that evidence-based use of optimal medical therapy (OMT), which consists of an antiplatelet agent, β blocker, statin, and angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), is an essential treatment for patients with CAD, including patients who have undergone coronary artery bypass grafting (CABG).1 x 1 Smith, S.C. Jr, Benjamin, E.J., Bonow, R.O., Braun, L.T., Creager, M.A., Franklin, B.A., Gibbons, R.J., Grundy, S.M., Hiratzka, L.F., Jones, D.W., Lloyd-Jones, D.M., Minissian, M., Mosca, L., Peterson, E.D., Sacco, R.L., Spertus, J., Stein, J.H., Taubert, K.A., and World Heart Federation, the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124: 2458–2473 Crossref | PubMed | Scopus (720) | Google Scholar See all References , 2 x 2 Kulik, A., Ruel, M., Jneid, H., Ferguson, T.B., Hiratzka, L.F., Ikonomidis, J.S., Lopez-Jimenez, F., McNallan, S.M., Patel, M., Roger, V.L., Sellke, F.W., Sica, D.A., Zimmerman, L., and American Heart Association Council on Cardiovascular and Stroke Nursing, Anesthesia. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015; 131: 927–964 Crossref | PubMed | Scopus (66) | Google Scholar See all References We have shown the limited efficacy of percutaneous coronary intervention (PCI) in post-CABG patients as a secondary revascularization because the effect of PCI is dependent on preprocedural coronary atherosclerosis.3 x 3 Miyagi, T., Asaumi, Y., Nishimura, K., Nakashima, T., Sakamoto, H., Nakao, K., Kanaya, T., Nagai, T., Shimabukuro, Y., Miyamoto, Y., Fujita, T., Kusano, K., Anzai, T., Kobayashi, J., Noguchi, T., Ogawa, H., and Yasuda, S. Validation of the Coronary Artery Bypass Graft SYNTAX Score (synergy between percutaneous coronary intervention with taxus) as a prognostic marker for patients with previous coronary artery bypass graft surgery after percutaneous coronary intervention. Circ Cardiovasc Interv. 2016; 9 (e003459) Crossref | PubMed | Scopus (2) | Google Scholar See all References Because post-CABG patients requiring secondary revascularization long after initial CABG have advanced coronary atherosclerosis, the efficacy of these medications in this patient population remains unclear. Thus, we sought to examine the effect of OMT and its components on patients with previous CABG who underwent secondary PCI.

1 January 2021 in JACC: Case Reports
Verified
Journal Article
Open access
TMTadayoshi Miyagi
Tadayoshi Miyagi
TITohru Ishimine
Tohru Ishimine
JNJun Nakazato
Jun Nakazato
NTNaoki Taniguchi
Naoki Taniguchi
NYNobuhito Yagi
Nobuhito Yagi
MWMinoru Wake
Minoru Wake
Coronary artery embolism due to BioGlue surgical adhesive after repair of type A acute aortic dissection is a rare condition. We report a case of BioGlue coronary artery embolism after type A acute aortic dissection repair confirmed using intravascular ultrasound imaging and pathological examination. It was successfully treated with percutaneous coronary intervention. (Level of Difficulty: Advanced.)

15 December 2020 in Respirology Case Reports
Verified
Journal Article
Open access
PDF file
AMAkiko Maeda
Akiko Maeda
DNDaijiro Nabeya
Daijiro Nabeya
HNHiroaki Nagano
Hiroaki Nagano
NYNobuhito Yagi
Nobuhito Yagi
TMTadayoshi Miyagi
Tadayoshi Miyagi
TKTomoo Kishaba
Tomoo Kishaba
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes coronavirus disease 2019 (COVID‐19), has resulted in significant morbidity and mortality worldwide. Approximately 5% of COVID‐19 patients who suffer from pneumonia develop critical respiratory failure. Here, we report the case of a healthy 52‐year‐old man who had respiratory failure owing to SARS‐CoV‐2 infection and was treated using femoro‐femoral veno‐venous extracorporeal membrane oxygenation (VV‐ECMO) and prone position ventilation (PPV). After this treatment, his blood oxygen levels, chest high‐resolution computed tomography findings, and clinical parameters significantly improved. He was decannulated from VV‐ECMO on day 6 and finally extubated on day 11. To our knowledge, this is the first reported case of SARS‐CoV‐2‐associated acute respiratory distress syndrome that was successfully treated with a combination of femoro‐femoral VV‐ECMO and PPV.